A5029656956- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Breast Lesions and Carcinomas
- Gastric Cancer Management and Outcomes
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Cancer and Skin Lesions
- Lymphoma Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- BRCA gene mutations in cancer
- AI in cancer detection
- PI3K/AKT/mTOR signaling in cancer
- Cell death mechanisms and regulation
- Lung Cancer Research Studies
- Estrogen and related hormone effects
- Medical Imaging Techniques and Applications
Ravensburg University of Cooperative Education
2016-2025
RWTH Aachen University
2025
Praxis für Hämatologie und Onkologie
2015-2024
University Hospital Münster
2006-2023
Ludwig-Maximilians-Universität München
2012-2023
Siemens (Germany)
2023
MVZ Labor Ravensburg
2017-2022
Dietrich Bonhoeffer Klinikum
2011-2021
University of Vienna
2008-2020
Helios Hospital Berlin-Buch
1999-2019
The purpose of this study is to obtain a consensus for the therapy B3 lesions. first International Consensus Conference on lesions uncertain malignant potential in breast (B3 lesions) including atypical ductal hyperplasia (ADH), flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary (PL), benign phyllodes tumors (PT), and radial scars (RS) took place January 2016 Zurich, Switzerland organized by Breast Ultrasound School Swiss Minimally Invasive Biopsy group-a subgroup...
BackgroundFIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature four different subtypes. Relevance of CMS for the treatment mCRC has yet be defined.Patients and MethodsIn this exploratory analysis, patients were grouped previously published tumor CRC-CMSs. Objective response rates (ORR)...
There is strong evidence that ductal carcinoma in situ (DCIS) represents a precursor lesion of invasive breast cancer. In order to analyse specific chromosomal alterations DCIS, 38 paraffin-embedded specimens DCIS and six associated carcinomas were examined by means comparative genomic hybridization (CGH). Losses 16q material seen almost exclusively well- intermediately-differentiated DCIS. These two subgroups differed the average number genetic imbalances, 2·5 5·5 respectively....
This study was performed to determine the diagnostic value of keratin 5/6 (CK 5/6) immunophenotyping on routinely processed breast tissues.Six hundred and ninety-nine lesions, including normal tissues as well benign malignant lesions in 321 formalin-fixed, paraffin-embedded samples from 158 different patients were investigated immunohistochemically, following wet autoclave pre-treatment for antigen retrieval. In tissues, both myoepithelial luminal epithelial cells expressed CK varying...
Cetuximab enhances the efficacy of chemotherapy in several cancer types. This trial assessed activity cetuximab and advanced gastric cancer.Patients with previously untreated, metastatic, received 400 mg m(-2) at first infusion followed by weekly infusions 250 combined FUFOX (oxaliplatin 50 m(-2), 5-FU 2000 DL-folinic acid 200 d1, 8, 15 22 qd36). The primary endpoint was tumour response.Overall, 52 patients were enrolled. most common grade 3/4 toxicities diarrhoea (33%), skin toxicity (24%)....
The International Consensus Conference on the treatment of primary breast cancer takes place every two years in St. Gallen, Switzerland. panel Gallen is composed international experts from different countries. From a German perspective, it seems reasonable to interpret voting results light AGO-recommendations and S3-guidelines for everyday practice Germany. Consequently, team eight experts, whom are members panel, commented (2013). main topics at this year's conference were surgical issues...
Purpose We investigated choice and efficacy of subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus cetuximab [arm A] or bevacizumab B]) for patients KRAS wild-type metastatic colorectal cancer. Patients Methods Start subsequent-line (second third) therapy was defined as use an antitumor drug that not part previous regimen. evaluated choice, duration, determined impact treatment outcome FIRE-3. Results Of 592 intent-to-treat population, 414...
Abstract Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab in KRAS wild-type metastatic colorectal cancer (mCRC) FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis aimed to determine whether cetuximab improves response and versus among response-evaluable patients receiving first-line RAS mCRC the effect of primary tumour side on outcomes. Methods The intent-to-treat population included 593 exon 2 mCRC. Further...
AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus oxaliplatin. This analysis the impact primary tumor location on outcome patients. Left-sided tumors were defined as from rectum to left flexure, while in remaining colon regarded right sided. Overall survival (OS), progression-free (PFS) response rate correlated location. A Cox regression model was used evaluate interaction between KRAS mutation. Of 146...